Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

I believe, that though many types of treatment "can" result in OM, Cellceutix added the exclusions you referenced to "limit" the data pool to treatment methods that had a "very high" likelihood of OM which limited the patient pool considerably.


" Mucositis affects between 20 percent and 40 percent of patients receiving conventional chemotherapy regimens for solid tumors, depending on the dose and cytotoxicity of the drug. In patients receiving high dose chemotherapy before a hematopoietic SCT, oral mucositis may be seen in up to 80 percent. Almost all patients receiving therapeutic radiation for head and neck cancer develop oral mucositis.4,5 Clinical examples of erythematous and ulcerative mucositis commonly seen in head and neck cancer therapy and in bone marrow transplant are shown in Figures 1,2, and 3."

http://www.oralhealthgroup.com/features/managing-oral-mucositis-cancer-therapy/

If they had just used the entire group of patients who "could" have developed OM the results would have been much more difficult to interpret accurately.